Novo Nordisk (NYSE:NVO) announced on Tuesday that Maziar Mike Doustdar will become its new president and chief executive officer, effective August 7, 2025. Doustdar, currently the executive vice president of International Operations, will succeed Lars Fruergaard Jørgensen, who will step down on the same date.
Helge Lund, Chair of Novo Nordisk, praised the appointment, saying, “Mike is an exceptional leader and has the unanimous support of the Board. We are confident he is the right person to guide Novo Nordisk through its next phase of growth.” The decision also has full backing from the Novo Nordisk Foundation.
Upon taking the helm, Doustdar remarked, “It’s an enormous privilege to lead this company during a time of great opportunity and change. I approach this role with urgency, a strong focus on performance, and a fierce determination to take Novo Nordisk to new heights.”
In addition to the CEO transition, Novo Nordisk revealed several organizational changes effective August 7. The executive vice president roles for Research & Early Development and Development will be merged into a single R&D unit led by Martin Holst Lange, who will be appointed the new chief scientific officer.
Marcus Schindler, the current executive vice president of Research & Early Development and Chief Scientific Officer, has decided to retire but will stay on temporarily to ensure a smooth handover.
Furthermore, Emil Kongshøj Larsen, senior vice president for the Europe and Canada region, will join Executive Management and succeed Doustdar as executive vice president of International Operations. Larsen currently oversees a region covering 40 countries and contributing about 20% of Novo Nordisk’s global sales.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.